A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.

Trial Details

NCT ID
NCT06090266
Phase
PHASE1 / PHASE2
Sponsor
OncoResponse, Inc.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • OR502
  • Cemiplimab
Locations (sample)
  • Austin, Texas, United States|30.26715,-97.74306
  • Irving, Texas, United States|32.81402,-96.94889
  • San Antonio, Texas, United States|29.42412,-98.49363
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Informed consent signed by the subject prior to conducting study-specific procedures.
  • Male or female subjects ≥ 18 years of age.
  • Histological diagnosis as follows:
  • Parts A and B (Cohorts A1, A2, and B1): subjects must have a histological diagnosis of any type of carcinoma, sarcoma, or melanoma with progressive…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →